Recent News

• 07.22.2026 - Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
• 07.22.2026 - Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
• 07.20.2026 - Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
• 07.20.2026 - Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
• 06.30.2026 - Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
• 06.30.2026 - Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
• 06.26.2026 - Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
• 06.26.2026 - Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
• 06.01.2026 - Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
• 06.01.2026 - Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Recent Filings

• 07.22.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 07.22.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 07.22.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 07.22.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 07.22.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 07.22.2026 - 8-K Current report
• 07.22.2026 - EX-99.1 EX-99.1
• 07.10.2026 - 144/A Report of proposed sale of securities
• 07.07.2026 - 144 Report of proposed sale of securities
• 07.02.2026 - 4 Statement of changes in beneficial ownership of securities